Catalyst Pharmaceuticals, Inc.
CPRX
Updated: 24/09/2026, 17:27:03
Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables, Florida, operates as a commercial-stage biopharmaceutical enterprise. This company is dedicated to discovering, developing, and marketing therapeutic solutions for individuals in the United States who are afflicted with uncommon, severe, and long-term neuromuscular and neurological disorders. Among its key offerings is Firdapse, an amifampridine phosphate tablet formulation approved for managing Lambert-Eaton Myasthenic Syndrome (LEMS). Catalyst also provides Ruzurgi, a specific treatment option for pediatric patients diagnosed with LEMS. Beyond its existing products, Catalyst is actively investigating additional applications for Firdapse, including its potential use in treating MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and hereditary neuropathy with liability to pressure palsies. The company engages in various strategic collaborations, such as licensing agreements with BioMarin Pharmaceutical Inc., and a joint development and commercialization agreement with Endo Ventures Limited concerning a generic version of Sabril tablets. Previously known as Catalyst Pharmaceutical Partners, Inc., the company adopted its current name in May 2015.
No summaries found.
- Share price
- $31.49
- Market cap
- $3.85B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Richard John Daly
- Employees
- 182
- IPO date
- 08/11/2006
- Beta
- 0.742
- Last dividend
- $0.00
- Day range
- $31.49 – $31.49
- 52-week range
- $19.05 – $32.56
- 1-day performance
- 0.00%
- 1-year performance
- 65.30%
- Current drawdown (1Y)
- -3.29%
- CIK
- 0001369568
- CUSIP
- 14888U101
- ISIN
- US14888U1016
- Created
- 07/12/2025, 03:25:36
- Last update
- 24/09/2026, 17:27:03
Track Catalyst Pharmaceuticals, Inc. with an AI analyst
See which prediction-market events move CPRX, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Catalyst (CPRX) Up 0.6% Since Last Earnings Report: Can It Continue?
Zacks Investment Research • STOCK • 10/06/2026, 14:31:13
Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term
Zacks Investment Research • STOCK • 27/05/2026, 12:50:23
Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term
Zacks Investment Research • STOCK • 25/05/2026, 12:41:29
CPRX or UTHR: Which Is the Better Value Stock Right Now?
Zacks Investment Research • STOCK • 14/05/2026, 14:41:09
Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y
Zacks Investment Research • STOCK • 12/05/2026, 14:20:16
Catalyst (CPRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Zacks Investment Research • STOCK • 11/05/2026, 21:30:40
Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc. - CPRX
Business Wire • STOCK • 09/05/2026, 22:21:00
Catalyst Pharmaceuticals (NASDAQ:CPRX) Acquisition: Earnings, Valuation, and Shareholder Scrutiny
Market Data • Market Data • 08/05/2026, 23:00:17
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) Acquisition: Oppenheimer Downgrades Stock
Market Data • Market Data • 07/05/2026, 19:05:55
Seeking Clues to Catalyst (CPRX) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
Zacks Investment Research • STOCK • 07/05/2026, 12:20:14
Catalyst Pharma to Be Acquired by Angelini Pharma in $4.1 Billion Deal
WSJ • STOCK • 07/05/2026, 05:15:00
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Hetero Labs Ltd.
GlobeNewsWire • STOCK • 07/05/2026, 04:44:00